Table 1.
Some small molecular modulators of estrogen-related receptors
Physiological effects | Molecular modulators | Targets | Notes | References |
---|---|---|---|---|
Inverse agonists | XCT790 | ERRα | The detailed molecular mechanism of XCT790 binding to ERRα remains ambiguous | Kokabu et al. (2019), Vitto et al. (2019) |
LingH2-10 | ERRα | IC50 = 0.64 ± 0.12 μM | Ning et al. (2017) | |
Thiazolidinediones | ERRα | Patch et al. (2011) | ||
Statins | ERRα | Inhibiting effect in vivo; Inverse effect in vitro | Tripathi et al. (2020) | |
DY40 | ERRβ | The most potent ERRβ inverse agonist | Yu et al. (2017) | |
GSK5182 | ERRγ | Relatively non‐toxic with an oral LD50 in mice of greater than 1000 mg/kg | Joo et al. (2015) | |
DY181 | ERRγ | The most potent ERRγ inverse agonist; IC50 = 0.01 μM | Yu et al. (2017) | |
Tetrasubstituted olefin analog | ERRγ | Kim et al. (2019b) | ||
4-OHT | ERRβ, ERRγ | Coward et al. (2001) | ||
TAM | ERRβ, ERRγ | Coward et al. (2001) | ||
DES | ERRα, ERRβ, ERRγ | Long-term use of DES can increase the risk of malignant tumors of the genital system | Lu et al. (2012) | |
Agonists | Cholesterol | ERRα | The detailed molecular mechanism of cholesterol binding with ERRα remains ambiguous | Casaburi et al. (2018); Li et al. (2019b) |
DY 131 | ERRβ | Tiek et al. (2019) | ||
GSK4716 | ERRγ | A potent ERRγ agonist with excellent selectivity over ERRα and ERRβ | Kim et al. (2009) | |
Flavone and isoflavone | ERRα, ERRβ | Suetsugi et al. (2003) | ||
GSK9089 | ERRβ, ERRγ | Zuercher et al. (2005) |